Please use this identifier to cite or link to this item: https://biore.bio.bg.ac.rs/handle/123456789/7192
DC FieldValueLanguage
dc.contributor.authorStepanović, Anaen_US
dc.contributor.authorTerzić Jovanović, Natašaen_US
dc.contributor.authorKorać, Aleksandraen_US
dc.contributor.authorZlatović, Marioen_US
dc.contributor.authorNikolić, Igoren_US
dc.contributor.authorOpsenica, Igoren_US
dc.contributor.authorPešić, Milicaen_US
dc.date.accessioned2024-05-20T08:26:31Z-
dc.date.available2024-05-20T08:26:31Z-
dc.date.issued2024-05-
dc.identifier.issn07533322-
dc.identifier.urihttps://biore.bio.bg.ac.rs/handle/123456789/7192-
dc.description.abstractTwo novel hybrid compounds, CON1 and CON2, have been developed by combining sclareol (SC) and doxorubicin (DOX) into a single molecular entity. These hybrid compounds have a 1:1 molar ratio of covalently linked SC and DOX. They have demonstrated promising anticancer properties, especially in glioblastoma cells, and have also shown potential in treating multidrug-resistant (MDR) cancer cells that express the P-glycoprotein (P-gp) membrane transporter. CON1 and CON2 form nanoparticles, as confirmed by Zetasizer, transmission electron microscopy (TEM), and chemical modeling. TEM also showed that CON1 and CON2 can be found in glioblastoma cells, specifically in the cytoplasm, different organelles, nucleus, and nucleolus. To examine the anticancer properties, the U87 glioblastoma cell line, and its corresponding multidrug-resistant U87-TxR cell line, as well as patient-derived astrocytoma grade 3 cells (ASC), were used, while normal human lung fibroblasts were used to determine the selectivity. CON1 and CON2 exhibited better resistance and selectivity profiles than DOX, showing less cytotoxicity, as evidenced by real-time cell analysis, DNA damage determination, cell death induction, mitochondrial respiration, and mitochondrial membrane depolarization studies. Cell cycle analysis and the β-galactosidase activity assay suggested that glioblastoma cells die by senescence following CON1 treatment. Overall, CON1 and CON2 showed great potential as they have better anticancer features than DOX. They are promising candidates for additional preclinical and clinical studies on glioblastoma.en_US
dc.language.isoenen_US
dc.publisherElsevier France ^Editions Scientifiques et Medicalesen_US
dc.relation.ispartofBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieen_US
dc.subjectcancer multidrug resistanceen_US
dc.subjectglioblastomaen_US
dc.subjecthybrid compoundsen_US
dc.subjectnanoparticlesen_US
dc.subjectsclareol, doxorubicinen_US
dc.titleNovel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastomaen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.biopha.2024.116496-
dc.identifier.pmid38537581-
dc.identifier.scopus2-s2.0-85188815917-
dc.identifier.urlhttps://api.elsevier.com/content/abstract/scopus_id/85188815917-
dc.description.rankM21en_US
dc.description.impact7.5en_US
dc.description.startpage116496en_US
dc.relation.issn0753-3322en_US
dc.description.volume174en_US
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptChair of Cell and Tissue Biology-
crisitem.author.orcid0000-0002-3044-9963-
Appears in Collections:Journal Article
Show simple item record

SCOPUSTM   
Citations

2
checked on Nov 4, 2024

Page view(s)

1
checked on Nov 4, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.